Poorni M. Manohar, MD

Research Reports

Bone-Modifying Agent Utilization: An Analysis in Patients With Metastatic Cancer and Bone Involvement at an NCI-Designated Cancer Center

04/12/2023

Kyle E. Bastys

Micah Tratt

Julie Gralow, MD, FACP, FASCO

Keith D. Eaton, MD, PhD

Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.

Manohar et al investigate the...

04/12/2023

Journal of Clinical Pathways

Research Reports

Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States

10/20/2021

Poorni M. Manohar, MD

Hannah M. Linden, MD

Josh A. Roth, PhD, MHA

Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.

Poorni M. Manohar, MD, et al...

10/20/2021

Journal of Clinical Pathways